NEW YORK, November 8, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Endo Health Solutions Inc. (NASDAQ: ENDP), Bristol-Myers Squibb Co. (NYSE: BMY), Express Scripts Holding Company (NASDAQ: ESRX), AbbVie Inc. (NYSE: ABBV), and Incyte Corporation (NASDAQ: INCY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Endo Health Solutions Inc. Research Report
On November 5, 2013, Endo Health Solutions Inc. (Endo) reported its Q3 2013 financial results. The Company's revenues declined 4.7% YoY to c.$715.0 million during the quarter. Net income attributable to Endo was $40.2 million or $0.33 per diluted share in Q3 2013, compared to $53.8 million or $0.45 per diluted share in Q3 2012. Commenting on the results, Rajiv De Silva, President and CEO of Endo, said, "Endo continues to evolve through what is an important transition period for the company. During the third quarter we have carried the momentum we established in June with the announcement of our new strategic direction. We have implemented a leaner operating model, announced progress in our branded pipeline, announced the acquisition of Boca Pharmacal and continued to assemble a strong leadership team to lead Endo towards our objective of creating a leading specialty healthcare company." The Full Research Report on Endo Health Solutions Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Bristol-Myers Squibb Co. Research Report
On November 2, 2013, Bristol-Myers Squibb Co. (Bristol-Myers Squibb) announced the submission of a New Drug Application (NDA) to Japan's Pharmaceutical and Medical Devices Agency seeking the world's first interferon-free and ribavirin-free treatment regimen for patients with chronic hepatitis C. According to the Company, the submission was based on results from a Phase III study demonstrating that the 24-week, all-oral, interferon-free and ribavirin-free regimen of daclatasvir (DCV) and asunaprevir (ASV) achieved an overall sustained virologic response 24 weeks after the end of treatment (SVR24) of 84.7% in Japanese patients with chronic hepatitis C (HCV) genotype 1b who were either interferon-ineligible/intolerant (87.4% SVR24) or non-responders (null and partial) to interferon-based therapies (80.5% SVR24). Brian Daniels, M.D., Senior Vice President of Global Development and Medical Affairs, Research and Development at Bristol-Myers Squibb, said, "With our submission in Japan, we are pleased to be one step closer to bringing a potential new treatment option to the many people living with HCV in that country." The Full Research Report on Bristol-Myers Squibb Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Express Scripts Holding Company Research Report
On November 4, 2013, Express Scripts Holding Company (Express Scripts) announced that the Company will present at the Credit Suisse Healthcare Conference on November 12, 2013 at 9:00 a.m. MST (11:00 a.m. EST) at the Phoenician Hotel in Scottsdale, Arizona. The Company added that its presentation will be broadcast via the Internet and can be accessed on the Investor Relations section of the Express Scripts website. The webcast will be archived and available for replay for 14 days. The Full Research Report on Express Scripts Holding Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
AbbVie Inc. Research Report
On November 5, 2013, AbbVie Inc's stock declined 1.21%, ending the day at $48.17. Over the previous three trading sessions, shares of AbbVie declined 0.58% compared to the S&P 500 which gained 0.37% during the same period. The Full Research Report on AbbVie Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Incyte Corporation Research Report
On October 31, 2013, Incyte Corporation (Incyte) reported its Q3 2013 financial results. The Company's total revenues increased 40.7% YoY to $85.1 million during the quarter. Net loss was $22.0 million or $0.14 per diluted share in Q3 2013, compared to net loss of $21.7 million or $0.17 per diluted share in Q3 2012. Commenting on the results, Paul A. Friedman, M.D., Incyte's President and CEO, said, "The growth of Jakafi remains strong, and we're encouraged by the sustained steady rate of new prescriptions for patients with myelofibrosis and continued evidence that physicians are successfully individualizing dosing. With potential approval of ruxolitinib for use in polycythemia vera in late 2014 and recent data from the RECAP trial that suggest potential benefit in pancreatic cancer and opportunities in other solid tumors, we see several drivers to further grow revenues for our first product, while we continue to deliver promising results for other compounds in our growing pipeline." The Full Research Report on Incyte Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner